Binnopharm Group's revenue under IFRS for 2024 increased by 12.9% to 36.7 billion rubles from 32.5 billion rubles a year earlier. Operating profit increased by 53.9% to RUB 6.2 billion. from 4 billion rubles . Adjusted EBITDA amounted to 9.6 billion rubles. Net debt at the end of the period is 19.8 billion rubles. This is stated in the company's message.
The goal for 2025 is to reduce the credit burden, make efficient use of resources, complete large—scale investment projects and further expand into international markets, said Hafiz Gafurov, the company's chief financial officer.
Binnopharm Group is a Russian pharmaceutical company that develops and manufactures prescription and over—the-counter medicines. Binnopharm Group unites production sites located in various regions of Russia: PJSC Sintez (Kurgan), JSC ALIUM (Obolensk in the Serpukhov district of the Moscow Region), JSC Binnopharm (Zelenograd), JSC Biocom (Stavropol) and a modern R&D center (Krasnogorsk). The company's products can be purchased in 15 countries.
